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Abstract 
Objective: Adrenocortical carcinoma (ACC) is an aggressive tumor that accounts for 0.02% of 
all reported cancers. ACC commonly arises in a sporadic manner, but may also manifest as 
part of a familial syndrome. Regardless of the setting, ACC rarely arises concurrent with other 
malignant tumors. 
Methods: In this report we describe a 32-year-old woman who on work-up for abnormal 
vaginal bleeding was diagnosed with synchronous uterine adenocarcinoma, ovarian adeno-
carcinoma and ACC. We also provide a literature review of the past 20 years to identify other 
patients with ACC and synchronous malignant tumors, and those with familial syndromes 
associated with an increased risk of developing ACC. 
Results and Conclusions: To our knowledge this is the first report of a patient with syn-
chronous malignant tumors of the uterus, ovary and adrenal gland. Review of the literature 
revealed only 5 other cases in which a patient had concurrent ACC and malignant tumors in 
other organs.  
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Introduction 
Adrenocortical carcinoma is a rare tumor with 
an estimated incidence of 1-2 per million per year. (1) 
It affects women nearly 60% more often than men and 
accounts for only 0.02% of all reported cancers. (2) 
These tumors arise with a peak bimodal age distribu-
tion during the first and fifth decades of life and 
2-10% can be bilateral. (2-4)  
The clinical presentation varies, ranging from 
vague, non-specific abdominal or back pain to overt 
hormonal syndromes when the tumors become bio-
chemically active. Between 57 and 67% of patients 
present with either local invasion or widely metastatic 
disease. (4, 5) The most common hormone secreted in 
ACC is cortisol, resulting in Cushing’s syndrome. 
Steroid overproduction is present in about 60% of 
patients with ACC. (6) In children, virilizing tumors 
are the most common functional adrenocortical tu-
mors and account for 20-30% of ACC. Despite our 
surgical, medical and chemotherapeutic advances, the 
overall prognosis of patients with ACC is dismal, with 
a 5-year survival of less than 35%. (7) 
Most ACCs arise sporadically; however, ACC 
does develop as part of a constellation of tumors in 
inherited familial cancer syndromes. The most com-
monly reported include the Li-Fraumeni Syndrome 
(8), Beckwith-Wiedemann Syndrome (BWS), Gardner 
Syndrome, and Multiple Endocrine Neoplasia, type 1. 
(9) Each syndrome is associated with a unique ger-
mline mutation. The commonality, however, is their 
inherit risk of developing ACC.  Despite the risk of 
developing ACC in an inherited fashion, the risk of 
developing synchronous ACC with other malignant 
tumors is exceedingly rare.  We report a patient who Journal of Cancer 2010, 1 
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was diagnosed with synchronous ovarian cancer, 
uterine cancer and ACC.  
Description of Case  
A 32-year-old woman with a history of vaginal 
bleeding presented to a referring hospital with edema 
of the left lower extremity. A computer tomography 
(CT) scan of the pelvis showed a left pelvic mass and a 
deep venous thrombosis. She underwent a uterine 
biopsy which revealed a grade I endometrial adeno-
carcinoma. A staging CT scan demonstrated a hete-
rogeneous central and left pelvic mass measuring 16.8 
x 14.8 cm and a 14.5 x 10.7 cm left adrenal mass. (Fig-
ure 1) Before she was referred to our institution, a 
biopsy of the adrenal mass  was done to exclude 
hormonal overproduction and interpreted as consis-
tent with an ACC. Magnetic resonance imaging fur-
ther delineated the pelvic mass as two separate 
masses: a 2.3 cm uterine mass and a 15.5 x 15.3 cm left 
adnexal mass. (Figure 2) 
 
Figure 1: Computed tomography scan showing a) 14.5 x 
10.7 cm left adrenal mass with areas of necrosis and internal 
calcifications, and b) 16.8 x 14.8 cm pelvic mass. Arrows 
denote the tumors. 
 
Figure 2: Magnetic resonance imaging scan showing a) 2.3 
cm uterine mass and b) 15.5 x 15.3 cm left adnexal mass. 
Arrows denote the tumors. 
 
Before surgery at our institution, an inferior vena 
cava filter was placed and hormonal activity was ex-
cluded from the adrenal tumor. The patient under-
went an exploratory laparotomy, total abdominal 
hysterectomy, bilateral salpingo-oophorectomy, pel-
vic lymph node dissection, omentectomy, abdominal 
washing and left adrenalectomy via a midline inci-
sion. Final pathologic examination revealed a stage I 
endometrioid adenocarcinoma, stage I adenocarci-
noma of the ovary and a stage II adrenocortical car-
cinoma. The adrenal tumor displayed 5 of 9 Weiss 
criteria (10) for malignancy: abundant necrosis, high 
mitotic count, atypical mitoses, nuclear pleomor-
phism and a diffuse architecture. The tumor did not 
exhibit the remaining criteria of non-clear cytoplasm, 
vascular invasion, capsular invasion or sinusoidal 
invasion. The patient received postoperative chemo-
therapy consisting of 6 cycles of paclitaxel and car-Journal of Cancer 2010, 1 
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boplatin. Mitotane was not given. She remains free of 
recurrence at 8 months after surgery. 
Literature Review 
The vast majority of ACCs arise sporadically, but 
ACC can develop in association with familial tumor 
syndromes.  Patients with these inherited syndromes 
have an increased risk of developing ACC, but the 
diagnosis of synchronous ACC with other cancers in 
these families has not to our knowledge been de-
scribed. The following syndromes are associated with 
ACC: 
Li- Fraumeni Syndrome 
Li-Fraumeni Syndrome (LFS) is an autosomal 
dominant disorder caused by a germ-line mutation in 
the TP53 gene located on chromosome region17q13.1. 
A mutation in this gene results in the inability of p53 
to initiate cell growth arrest and DNA repair. (3) The 
resulting cascade of events leads to the formation of a 
myriad of tumors including soft tissue sarcomas, os-
teosarcomas, breast cancer, brain tumors, and leuke-
mia.(9) ACC develops in approximately 3-4% of pa-
tients with LFS, most commonly in those under 20 
years of age. (3) 
Beckwith-Wiedemann Syndrome 
The Beckwith-Wiedemann Syndrome (BWS) re-
sults from an epigenetic dysfunction of the chromo-
somal region 11p15. This syndrome arises most often 
sporadically, but 15% of cases are familial. (3) The 
genes located in this region are the insulin-like growth 
factor 2 (IGF-2), cyclin-dependent kinase inhibitor 1C 
(CDKN1C, p57kip2), and H19. (3) Abnormalities in 
these genes result from parental imprinting that 
causes a gain in the paternal allele and loss of the 
maternal allele. This leads to the overgrowth sequela 
t h a t  i s  c h a r a c t e r i s t i c  o f  B W S .   P a t i e n t s  s u f f e r  f r o m  
macrosomia, exomphalos, macroglossia, abdominal 
wall defects, ear anomalies, renal abnormalities, and 
cleft palate. Patients also develop nephroblastoma, 
hepatoblastoma, rhabdomyosarcoma and nesideob-
lastosis. Additionally, ACC arises in 5% of patients 
with BWS. (3) 
Gardner Syndrome 
Gardner syndrome (11) is a disorder inherited in 
an autosomal dominant fashion that results in an in-
herit risk of developing colorectal cancer. This syn-
drome results from mutations in the APC gene in the 
chromosomal region 5q21. (3) The manifestation of 
this syndrome was first described in the early 1950’s 
as a combination of gastrointestinal polyps, osteomas 
and soft tissue tumors. (12) This syndrome is charac-
terized by epidermal cysts, gastric and duodenal po-
lyps, desmoid tumors, periampullary cancer, and 
about 2% of women with this syndrome develop a 
crifiborm type of papillary thyroid cancer. (13) 
Adrenocortical carcinoma also affects individuals 
with Gardner’s syndrome. Few cases have been de-
scribed in the literature since the original report by 
Marshall (14), so the precise prevalence is unknown.  
MEN1 Syndrome 
Multiple Endocrine Neoplasia 1 is a syndrome 
resulting from mutation in the MEN1 gene located in 
the chromosomal region 11q13. (9) The resulting mu-
tation leads to a defect in the MENIN protein, leading 
to the formation of pituitary tumors, parathyroid tu-
mors and pancreatic neuroendocrine tumors, as well 
as adrenal tumors, multiple lipomas and angiomas. 
Adrenocortical tumors develop in 55% of people af-
fected with this syndrome; the majority being ade-
nomas and less commonly ACC. (3) 
Synchronous Tumors 
The development of synchronous tumors in pa-
tients diagnosed with ACC occurs even more infre-
quently and is evidenced by the scarcity of reports in 
the English language literature.  A Pubmed literature 
using the key terms “adrenocortical carcinoma and 
synchronous tumors”, “adrenocortical carcinoma and 
synchronous cancer”, “adrenal cancer and malignan-
cies”, “adrenal cancer and ovarian cancer”, “ACC and 
synchronous cancer” and “ACC and malignancies” 
search revealed only five patients with synchronous 
tumors. The first case, described in 1995, was of a pa-
tient with cancer of the rectum, breast and adrenal 
gland. (15) ACC has also been reported to occur syn-
chronously with stage IIIB testicular seminoma (16), 
ganglioneuroblastoma (17), osteosarcoma (18), and 
renal cell carcinoma (19). (Table 1) 
Synchronous tumors appear to develop inde-
pendent of familial syndromes. The genetic abnor-
malities in these syndromes and subsequent devel-
opment of metachronous tumors raise the suspicion 
for a genetic component. Two patients showed a mu-
tation of the p53 gene; one showed a single base 
substitution in codon 248 (17) and the other had a 
mutation at codon 273. (18) Our patient underwent 
molecular testing for possible Lynch syndrome, given 
the high association of endometrial cancer with this 
syndrome, but she was not found to have microsatel-
lite instability. Additionally, the patient was found to 
not have a mutation of the p53 gene. 
Conclusion 
Although patients with familial syndromes are 
at higher risk of developing ACC, reports in the lite-Journal of Cancer 2010, 1 
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rature of synchronous ACC and other malignant tu-
mors are scant. To date, only 5 cases have been re-
ported of synchronous malignant tumors in patients 
with ACC.  There appears to be no association be-
tween the histological types of cancers that arise 
synchronously since all 5 cases had tumors of differ-
ent origin.   
To our knowledge, this is the first report of 
synchronous cancers arising in the adrenal gland, 
uterus and ovary. This is the only patient who has 
been diagnosed with synchronous tumors from the 50 
(2%) patients in our ACC tumor registry. Further-
more, no patients were diagnosed with metachronous 
tumors arising within a year of ACC diagnosis. This 
denotes not only the rarity of ACC, but also the rarity 
of developing synchronous cancers. 
 
Table 1: Reports of patients with ACC and synchronous malignancies 
Published Study  Patient Age  Synchronous Tumor  ACC Stage  Duration of recur-
rence free disease 
Eisinger, et al., 1983 (15)  n/a  Breast, Rectal  n/a  n/a 
Inoue, et al., 1998 (16)  57y  Testicular seminoma  II  42 months 
Pivnick, et al., 1998 (17)  18m  Ganglioneuroblastoma  IV 
(Metastases to lung) 
17 months 
Khayat, et al., 2004 (18)  7y  Osteosarcoma  IV 
(Renal invasion) 
Died from osteosar-
coma metastases 
Jani, et al., 2008 (19)  53y  Renal cell carcinoma  III  24 months 
Guerrero, et al.   32y  Ovarian and Uterine carcinoma  II  8 months 
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